Dr. Corey and colleagues reply

New England Journal of Medicine

Volumn 371, Issue 12, 2014, Pages 1162-1163

  Corey, G Ralph ^a   Jiang, Hai ^b   Moeck, Greg ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICINES COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; GLYCOPEPTIDE; TEICOPLANIN;

BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG RESPONSE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION RATE; INTENTION TO TREAT ANALYSIS; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; SKIN INFECTION; BACTERIAL SKIN DISEASE; FEMALE; MALE; NOTE;

ANTI-BACTERIAL AGENTS; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; SKIN DISEASES, BACTERIAL; TEICOPLANIN; VANCOMYCIN;

EID: 84907392537     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407925     Document Type: Letter

References (2)

1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2012: annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2013.
2. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013;19(9):E377-E385.